CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fu

ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Esti

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage biotechnology company, today annou

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechno

The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio I

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated comm

ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC

ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth an

Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearis

Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sec

ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, empha

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than av

Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun conc

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could st

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals a

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA revie

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has b

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

The Avis Budget short squeeze appears to be spreading to other stocks like Beyond Meat, Opendoor and

U.S. stocks higher as Dow Jones gains 300 points; El Pollo LoCo Holdings jumps 17.6% on better-than-

These 10 stocks posted best or worst months ever in January. Earnings surprises, AI disruption and s

Here's a look at the top 10 most heavily shorted stocks, including Lucid, MARA, Avis, Kohl's

Editor’s Note: The future prices of benchmark tracking ETFs, the lede and the headline were updated

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday